Catalog5 refs
Enfuvirtide
Immune ModulationResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
cells (HIV entry inhibition)
Overview
A 36-amino-acid synthetic peptide and the first HIV fusion inhibitor, FDA-approved in March 2003. It blocks HIV from entering host cells by binding to the gp41 protein's HR1 region, preventing viral-cell membrane fusion. Reserved for salvage therapy in treatment-experienced patients whose virus has stopped responding to other drugs. Commercially discontinued in February 2025 due to availability of superior alternatives.
Primary Uses
HIV salvage therapy
HIV fusion inhibition
Treatment of multi-drug-resistant HIV
Protocol Reference
Dose
90 mg subcutaneous twice daily
Frequency
Twice daily
Route
Subcutaneous injection
Evidence
FDA Approved
Research References· 4
https://pubmed.ncbi.nlm.nih.gov/16302461/
PubMedPMID 16302461- [https://pubmed.ncbi.nlm.nih.gov/12167274/](https://pubmed.ncbi.nlm.nih.gov/12167274/)
https://pubmed.ncbi.nlm.nih.gov/12167274/
PubMedPMID 12167274- [https://pubmed.ncbi.nlm.nih.gov/14998221/](https://pubmed.ncbi.nlm.nih.gov/14998221/)
Research Models
Human
Also in Immune Modulation